Open an account

Bioatla

BCAB · NASDAQ

$1.33+$0.02 (+1.53%)TodayMarket closed ·
Prev close $1.31

About BCAB

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Employees
41
Headquarters
San Diego, California
Listed
Dec 16, 2020
Sector
Health Care
Industry
Biotechnology
Website
bioatla.com

BCAB key statistics

Market cap
2.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
131.40K
Volume
5.34K
Open price
$1.36
High today
$1.53
Low today
$1.30
52 Week high
$71.50
52 Week low
$2.81

Bioatla (BCAB) at a glance

As of Oct 20, 2026, Bioatla (BCAB) shares are priced at $1.33, giving the company a market cap of 2.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.30 and $1.53. The current price is 2.3% above the day's low and 12.8% below its high.

Volume so far is 5.34K shares, below the average of 131.40K shares a day.

Over the past year Bioatla has ranged from $2.81 to $71.50, and now sits -2% of the way up that range.

Bioatla met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q4 FY25 it reported -$8.00 per share against an estimate of -$12.24.

BCAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 19.5% on average.

  1. Q1 FY24: reported -$24.00 per share against an estimate of -$27.64
  2. Q2 FY24: reported -$22.00 per share against an estimate of -$22.34
  3. Q3 FY24: reported -$11.00 per share against an estimate of -$18.36
  4. Q4 FY24: reported -$15.00 per share against an estimate of -$19.38
  5. Q1 FY25: reported -$13.00 per share against an estimate of -$17.68
  6. Q2 FY25: reported -$16.00 per share against an estimate of -$17.21
  7. Q3 FY25: reported -$13.50 per share against an estimate of -$15.13
  8. Q4 FY25: reported -$8.00 per share against an estimate of -$12.24

BCAB news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Similar companies

Companies in the same industry as Bioatla

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.